Dr. Woodnutt joined Tanabe Research Labs in March 2018 as Vice President of Development. Before joining TRL Dr. Woodnutt acted as a consultant to several small companies in both Research and Development areas to critically evaluate their ongoing projects as well as to provide planning and oversight for Development projects. Dr. Woodnutt served as CSO of Lpath until December 2016 where he led all Discovery and Development activities concerning the exploitation of monoclonal antibodies to bioactive lipids. Prior to that, Dr. Woodnutt served as the Vice President, Open Innovation at Pfizer/CovX from 2012 to 2013, but his primary role at CovX, from 2006 to 2012, was as Vice President of Biology Research. From 2002 to 2006, Dr. Woodnutt was the Senior Vice President of Pharmaceutical Research and Development for Diversa Corporation. He began his career in the pharmaceutical industry with Glaxo SmithKline Pharmaceuticals, where he was employed for more than 20 years becoming Vice President and Head of Biology in the Antimicrobial and Host Defense Group. Dr. Woodnutt received his Ph.D. in biochemistry/physiology from the University of Reading, and he has authored numerous scientific articles.